Phase 1-2a Dose-Ranging Study of TLK199 Tablets in Myelodysplastic Syndrome (MDS)

NCT00280631 Phase 1/Phase 2 COMPLETED

The purpose of this study is to determine the safety and efficacy of TLK199 Tablets in patients with Myelodysplastic Syndrome (MDS)

Details

Lead sponsor	Telik
Phase	Phase 1/Phase 2
Status	COMPLETED
Enrolment	49
Start date	2006-02
Completion	2008-06

Conditions

• Myelodysplastic Syndrome (MDS)

Interventions

• Ezatiostat Hydrochlorine

Primary outcomes

• Maximum Tolerated Dose or Optimal Biologic Dose — 6 months

Countries

United States